Aldesleukin is under clinical development by Clinigen and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase II drugs for Amyotrophic Lateral Sclerosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Aldesleukin’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Aldesleukin overview

Aldesleukin (Proleukin) is an immunoregulatory and antineoplastic product. It is a lymphokine that is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. It is formulated as lyophilized powder for solution for subcutaneous, intravenous administration. Proleukin is indicated for the treatment of adults with metastatic kidney cancer (renal cell carcinoma). Further, the drug is indicated for the prevention of metastatic melanoma for adults patients.

Aldesleukin is under development for the treatment of graft versus host disease and common variable immunodeficiency. It was also under development for the treatment of HIV/AIDS, acute myelocytic leukemia, B-cell non-Hodgkin lymphomas including indolent lymphoma, mantle cell lymphoma, follicular lymphoma, amyotrophic lateral sclerosis.

Clinigen overview

Clinigen is a pharmaceutical and services company that provides access to clinical trials, medicines, unlicensed and commercial supplies. The company’s products include dexrazoxane, crisantaspase, amifostine, foscarnet sodium, acetylcysteine, colecalciferol, folic acid, gabapentin, glycopyrronium bromide, iloprost, and others. It carries out clinical trial services, partnering, IDIS managed access, clinical supply management, and others. Clinigen‘s clinical trial services comprise packaging and labeling, direct-to-site delivery, global storage and distribution, ancillary supply sourcing, and controlled drug services. The company serves biotechnology and pharmaceutical companies; and healthcare professionals. It operates in Japan, the US, New Zealand, Australia, Singapore, South Africa, and the UK. Clinigen Group is headquartered in Burton-on-Trent, Staffordshire, the UK.

For a complete picture of Aldesleukin’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.